NASDAQ:MNOV

MediciNova Q2 2025 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova met analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.07 versus the -$0.07 consensus estimate, while revenue was $140 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.07
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
$140 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q2 2025 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.07 per share for Q2 2025, matching the consensus estimate of -$0.07. The report was announced on Thursday, August 14, 2025.

MediciNova reported revenue of $140 thousand for Q2 2025.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
Chase, Wells Fargo and Capital One all showed errors on Nov. 16
On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when trying to reach their money. The outage lasted hours. Cedar Gold Group points out that physical gold has no login, no server and needs no one's permission. Its free Wealth Protection Playbook shows how to keep part of your savings outside the banking system.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile